Tada Medical AB



Developed by Tada Medical AB


Intravenous (IV) therapy is the most common invasive procedure in modern healthcare, with fluids delivered directly into the vein through tubing connected to a catheter device. Of the 3.8 billion IV tubes used each year, research shows that ~10% of tubes are forcefully ripped from the vein during the infusion. This IV dislodgement can result in injury to the patient, loss of fluid resources, exposure of hazardous drugs and increased risk of infection. It also creates additional work for clinicians, with up to 30 mins of additional time required to clean and reinstate the infusion.


ReLink® is a patented breakaway connector, designed and engineered to increase safety and reduce harm caused by accidental dislodgement incidents.

Its unique design features double-sided, self-sealable ports, with weak link activation to protect the catheter placement site and loss of fluid resources. The pull force required to separate the tube from the catheter has been optimised through rigorous testing to ensure the catheter dwelling site remains protected.

After separation, both ReLink® connector parts can be simply swabbed and reconnected for rapid reinstatement of therapy, providing unrivalled efficiency for nursing staff in every environment.

ReLink® is specially engineered to enhance infusion stability by keeping connections of IV catheters to IV lines, with a controlled break away and predictable results. 

Hover over ReLink®

ReLink® product family

ReLink® is a platform technology which is adaptable across a broad range of sectors...

Hover over the image

Hover over the image

Hover over the image

Hover over the image


Meet the team

Katarina Hedbeck

Chief Executive Officer 

& Co-founder

Dr. Rebecca Bejhed

Chief Operating Officer

& Co-founder


ReLink® is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge in hospital and homecare infusions.

The patented ReLink®  platform technology will enable healthcare providers to deliver critical fluids safely and efficiently.

ReLink® is pending regulatory approval and is not yet for sale



A snapshot of what's keeping us inspired, excited and busy! 


"The project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 961967."


Tada Medical AB

keeping connections

Regeringsgatan 82
111 39 Stockholm, Sweden

  • Tada Medical AB Facebook Handle
  • Tada Medical AB LinkedIn Handle
  • Tada Medical AB YouTube Handle
  • Tada Medical AB Instagram Handle

© 2021 by Tada Medical AB  |  All rights reserved